| Drug-Target Information | ||||||||
|---|---|---|---|---|---|---|---|---|
| Drug Name | Target Name | Drug Type | Target Type | Source | Drug MeSHID | Interaction Score | Drug Status | Target Action |
| abt-263 | apoptosis regulator bcl-2 | NA | Successful target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Primary Myelofibrosis[MeSHID:D055728] Chronic Lymphocytic Leukemia[MeSHID:D015451] Malignant Neoplasms[MeSHID:D009369] Relapse[MeSHID:D012008] |
0.72 | phase 3 | unknown |
| abt-263 | apoptosis regulator bcl-xl | NA | Clinical trial target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Primary Myelofibrosis[MeSHID:D055728] Chronic Lymphocytic Leukemia[MeSHID:D015451] Malignant Neoplasms[MeSHID:D009369] Relapse[MeSHID:D012008] |
2.65 | phase 3 | unknown |
| abt-263 | apoptosis regulator bcl-w | NA | Clinical trial target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Primary Myelofibrosis[MeSHID:D055728] Chronic Lymphocytic Leukemia[MeSHID:D015451] Malignant Neoplasms[MeSHID:D009369] Relapse[MeSHID:D012008] |
2.65 | phase 3 | unknown |
| abt-263 | g1/s-specific cyclin-d1 | NA | Clinical trial target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Primary Myelofibrosis[MeSHID:D055728] Chronic Lymphocytic Leukemia[MeSHID:D015451] Malignant Neoplasms[MeSHID:D009369] Relapse[MeSHID:D012008] |
0.27 | phase 3 | unknown |
| click here to return to the previous page | ||||||||